[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 909
Citations 0
Comment & Response
August 21, 2013

Polypill for Cardiovascular Disease Prevention

Author Affiliations
  • 1Department of Primary Care Health Sciences, University of Oxford, Oxford, England
JAMA. 2013;310(7):749. doi:10.1001/jama.2013.16367

To the Editor Dr Smith and colleagues1 noted that “there appears to be little support for such a radical approach at least at present” in regard to the current situation facing combination therapies for cardiovascular disease prevention. However, the authors failed to outline any of the valid reasons behind this limited support, especially when focused on primary prevention. They instead quoted supply-side barriers and resistance due to the inevitable imperfect titration of individual therapies as the main culprits.

First Page Preview View Large
First page PDF preview
First page PDF preview